Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its quarterly earnings data on Friday. The specialty pharmaceutical company reported ($0.83) EPS for the quarter, Zacks reports.
Titan Pharmaceuticals Trading Up 1.3 %
Shares of NASDAQ TTNP opened at $3.23 on Friday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The stock has a 50 day moving average of $3.72 and a 200-day moving average of $4.95.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Saturday. They issued a “sell” rating for the company.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Where to Find Earnings Call Transcripts
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What is a Dividend King?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What is Put Option Volume?
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
